$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Which lung cancer patients is Sutolaxib (AMG 510) suitable for and prediction of drug effects?
2026-02-01 22:25:32
Check Details
Estimated launch time and market prospects of Krazati in the country
2026-02-01 22:25:32
Check Details
Analysis of the mechanism of action of Pimitespib and its advantages in targeted therapy
2026-02-01 22:25:32
Check Details
How long does it take to develop resistance to afatinib (Gitari) and how to deal with it
2026-02-01 22:25:32
Check Details
Precautions and scientific and safe medication guidelines for the use of DaliRasheng (Keweike)
2026-02-01 22:25:32
Check Details
Detailed explanation of the efficacy, functions and applicable groups of Lynparza (Lipdrox)
2026-02-01 22:25:32
Check Details
The best time to take venetoclax/venetoclax (venetoclax) and suggestions for medication and meal preparation
2026-02-01 22:25:32
Check Details
Evaluation of the clinical efficacy of Asnib/Asiminib (Sinbel) in the treatment of chronic myelogenous leukemia
2026-02-01 22:25:32
Check Details
Latest price information and purchasing recommendations for Ritlecitinib
2026-02-01 22:25:32
Check Details
Analysis on whether long-term medication is necessary after taking Sparsentan
2026-02-01 22:25:32
Check Details
Is there a patient assistance program and application guidelines for Ixazomib?
2026-02-01 22:25:32
Check Details
Analysis of Lurbinectedin price trends and future reference trends
2026-02-01 22:25:32
Check Details
1
2
...
2169
2170
2171
2172
2173
2174
2175
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
2
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
3
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
4
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
5
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
6
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
7
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
8
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
9
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
10
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
11
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide
12
Sabril (Vigabatrin) Explained: Indications, Vision Loss Risk & Key Warnings